Impact Therapeutics (07630) Report Interpretation

Overview

The report examines Impact Therapeutics' commercial expansion for senaparib, upcoming oncology data catalysts and progress in building new drug platforms. Goldman Sachs sees the Pharmanovia partnership as supportive of global expansion but retains a Neutral rating and lowers its target price to HK$33.1.

Core views

Impact Therapeutics has granted Pharmanovia exclusive ex-China rights to senaparib, a PARP1/2 inhibitor, for Europe, the Middle East, North Africa, Australia and New Zealand. The agreement could extend the product's reach to 66 countries and provides for up to EUR423.5mn in total payments, with the upfront payment undisclosed, plus tiered royalties of up to the mid-twenties percentage of net sales. Goldman Sachs regards the transaction as an incremental step in building senaparib's global commercial footprint. Management expects EMA approval for first-line ovarian-cancer maintenance therapy in 2H26; following approval, it aims to enter major EU markets and secure reimbursement within two years, while approvals in the Middle East and ANZ are anticipated within one year. The principal 2H catalyst is expected to be ESMO data in October. These include updated Phase III results for senaparib in first-line ovarian cancer with longer follow-up; management expects median progression-free survival to reach about 40 months. The company will also present Phase I/II data for IMP1734, a selective PARP1 inhibitor, as monotherapy and in combinations with paclitaxel in solid tumours and abiraterone in prostate cancer, as well as Phase I dose-escalation data for CNS-penetrant PARP1 inhibitor IMP1707 in HRR-mutated solid tumours. Management argues that IMP1734's higher selectivity and lower haematologic toxicity differentiate it from competing PARP inhibitors such as saruparib and could make it an attractive combination backbone. The Phase II monotherapy study is evaluating two dose levels; the company is prioritising prostate cancer and targets Phase III entry next year. For IMP1701, management identified glioblastoma and brain metastases as the main focus areas. Beyond synthetic lethality, management reiterated a multi-platform strategy. Its dual-payload ADC lead, IMP32, targets CEACAM5 with ATR and TOP1 payloads, has achieved preclinical-candidate status and is targeting an IND in 2H27, initially in colorectal cancer. Management expects the payload combination to be applicable to additional targets over time. The PROTAC platform uses proprietary E3 ligase and linker technology intended to improve solubility and oral absorption; IMP27, a KAT6A degrader, is expected to reach preclinical-candidate status shortly and enter clinical trials in 2H27, initially in ER+/HER2- breast cancer. Goldman Sachs lowered its 2026E/2027E/2028E EPS forecasts from RMB(0.50)/RMB1.32/RMB0.41 to RMB(0.47)/RMB1.32/RMB0.44. The changes reflect the Pharmanovia deal terms and updated IMP1734 assumptions aligned with the latest clinical-development plan, while the detailed indication plan remains unclear. The report lowered the probability of success for IMP1734 in first-line ovarian cancer from 36% to 14%. The 12-month target price is reduced to HK$33.1 from HK$37.6. It combines 70% risk-adjusted DCF value of HK$19.0 with 30% M&A value of HK$14.1, using a 14.0% discount rate, 3% terminal growth and stage-based, clinically adjusted probabilities of success. The M&A component applies a 12x EV/sales multiple to 2031E, defined as the second fiscal year after IMP1734's potential launch. Goldman Sachs describes Impact as a commercial-stage precision-oncology company with a leading PARP franchise, broader synthetic-lethality pipeline and emerging modalities, but remains Neutral-rated.

Analysis framework

Goldman Sachs assesses the licensing transaction and expected regulatory path for senaparib, then reviews upcoming clinical readouts and the development plans for pipeline assets and technology platforms. It updates earnings estimates and values the company through a probability-adjusted DCF, supplemented by an M&A component based on an EV/sales multiple.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted DCF valuation

  The report values future cash flows after applying stage-based probabilities of success and clinical-data adjustments, then discounts them at a 14.0% rate with 3% terminal growth.

• Valuation methodsEV/EBITDA valuation

  M&A value using a 12x EV/sales multiple

  Goldman Sachs assigns 30% of the target-price calculation to an acquisition-value component using 12x 2031E EV/sales for IMP1734 after launch.

• Industry AnalysisSupply-demand framework

  Commercialization and reimbursement rollout assessment

  The report evaluates the timing of regulatory approvals, market entry and reimbursement coverage as drivers of senaparib's ex-China sales expansion.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Impact Therapeutics (7630.HK)

  Primary covered company; its valuation is linked to senaparib commercialization, clinical readouts and pipeline execution.

  Strengths

  Leading PARP franchise, broad synthetic-lethality-focused pipeline, emerging modalities and experienced management.

  Weaknesses

  Limited commercial manufacturing and sales track record.

  Comparison

  IMP1734 is described as potentially differentiated from saruparib through higher selectivity and reduced haematologic toxicity.

  Risks

  Clinical outcomes, partner execution, talent retention, commercialization capability and senaparib revenue ramp-up.

Key data

• Pharmanovia agreement valueUp to EUR423.5mnTotal potential consideration; upfront payment undisclosed.
• Ex-China commercial reach66 countriesPotential countries covered by the Pharmanovia agreement.
• Senaparib EMA approval timing2H26Expected for first-line ovarian-cancer maintenance therapy.
• Senaparib median PFS expectationc.40 monthsManagement expectation for updated Phase III first-line ovarian-cancer follow-up.
• IMP1734 first-line ovarian-cancer probability of success14%Reduced from 36%.
• 2026E/2027E/2028E EPSRMB(0.47)/RMB1.32/RMB0.44Revised from RMB(0.50)/RMB1.32/RMB0.41.
• 12-month target priceHK$33.1Reduced from HK$37.6.
• Valuation weighting70% risk-adjusted DCF and 30% M&A valueDCF value HK$19.0 and M&A value HK$14.1.

Impact & implications

The report sees the Pharmanovia arrangement as broadening senaparib's route to overseas commercialization, while ESMO data and the development trajectory of IMP1734 and IMP1707 remain central near-term determinants. The lower target price reflects revised deal assumptions and a materially lower probability of success for IMP1734 in first-line ovarian cancer.

Risks

• Clinical development for PARP1 and other synthetic-lethality therapies could progress or deliver outcomes better or worse than expected.
• Pharmanovia's ex-China development and commercialization commitment and execution could be stronger or weaker than expected.
• Challenges recruiting and retaining talent could affect R&D execution and competitiveness.
• A limited commercial manufacturing and sales track record could constrain commercialization capability build-out.
• Senaparib's contribution and revenue ramp-up could be higher or lower than expected.

What to watch

• EMA approval timing for senaparib in first-line ovarian-cancer maintenance therapy in 2H26.
• October ESMO updates for senaparib, IMP1734 and IMP1707.
• EU market entry and reimbursement progress after senaparib approval.
• IMP1734 dose-selection, prostate-cancer development and targeted Phase III entry next year.
• Progress of IMP32 and IMP27 toward planned 2H27 clinical milestones.